Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 120,238

Document Document Title
WO/2016/188972A1
The present invention relates to novel compounds which are selective inhibitors of diacylglycerol lipase alpha and beta. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused ...  
WO/2016/190750A1
Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta- casein to the animal for consumption, where the beta-casein c...  
WO/2016/188381A1
The present invention relates to the technical field of medical compounds, and relates to an oxidized β-1,4-oligoglucuronic acid, and a preparation method therefor and uses thereof. In the present invention, by using abundant cellulose ...  
WO/2016/187718A1
A controlled extended release composition comprising at least one unit dosage form having at least one active pharmaceutical ingredient (API), wherein said at least one API comprises at least one of pregabalin, a base thereof, a pharmace...  
WO/2016/188684A1
The present invention refers to a process for preparing an animal brain extract. It also refers to the brain extract obtainable according to said process and to the use thereof as a medicine, in particular for the prevention and/or treat...  
WO/2016/189163A1
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2',3'-cyclic-nucleotide 3'-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagno...  
WO/2016/188828A1
Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for examp...  
WO/2016/190395A1
Provided is a composition that can be used to suppress microglia inflammation and is based on the discovery of oligopeptides that have a superior anti-inflammatory effect on microglia. The inflammation-suppressing action of dipeptides wa...  
WO/2016/190307A1
The present invention addresses the problem of finding a component that is capable of effectively exerting various effects of, for example, protecting brain function, preventing or ameliorating deterioration of cognitive ability and prev...  
WO/2016/188827A1
Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for examp...  
WO/2016/186772A3
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/187339A1
Galantamine and its pharmaceutically acceptable salts are of use in treating persons meeting criteria for having a risk of developing Alzheimer's type dementia, before dementia occurs by reducing the decline of Aβ amyloid in CSF or the ...  
WO/2016/184911A1
The present invention relates to methods and pharmaceutical compositions for the treatment of the neuropathology of patients suffering from myotonic dystrophy type 1 (DM1). In particular, the present invention relates to a method of trea...  
WO/2016/186154A1
It is found that the therapeutic efficacy of an IL-6 inhibitor on an MS patient can be predicted by employing, as a measure, the amount of plasmablasts and/or an index of a change of immature plasmablasts (e.g., the amount of immature pl...  
WO/2016/185468A1
The present invention provides pharmaceutical compositions comprising opioids and N-acylethanolamines, and methods for their use in preventing and treating a variety of opioid- responsive conditions and opioid-related side-effects.  
WO/2016/186140A1
The present invention addresses the problem of providing a novel membrane permeability-improving agent which can be applied to polymeric drugs. More specifically, the present invention addresses the problem of providing: a drug carrier w...  
WO/2016/184121A1
A new compound (as shown in formula I) and salts thereof, which are proved to be used for treating and preventing cerebral ischemic diseases and improving sleep by experiments. When R=H, salts are respectively generated by the compound t...  
WO/2016/185443A1
The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancemen...  
WO/2016/186967A1
The present disclosure provides indoleamine 2,3 -dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and R1 are as defined herein, as well as pharmaceutic...  
WO/2016/186184A1
The objective of the present invention is to provide: a crystal having high purity and excellent properties (such as stability and solubility) of a highly safe compound with few side effects, said compound having μ-opioid receptor antag...  
WO/2016/185160A1
A first aspect of the- invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, (Formula (I)) wherein: R1 is (CH2)mNR11R12;R2 is selected from H, halo, OR13, ΝΗR13, alkyl, alkenyl and alky...  
WO/2016/184310A1
The present invention relates to 4-methyl-1H-diaryl pyrazole derivatives, and specifically relates to the compounds represented by formula (I) and stereoisomers, solvates or pharmaceutically acceptable salts thereof. The present inventio...  
WO/2016/186204A1
Provided are a micelle for nucleic acid delivery using a temperature-sensitive polymer, and a method for producing the micelle. For example, provided is a polyion complex comprising a temperature-sensitive copolymer and a nucleic acid, w...  
WO/2016/185032A1
The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more spec...  
WO/2016/187595A3
An oral modified release pharmaceutical composition of methylergonovine suitable for oral once daily administration is provided. The composition includes at least about 0.6 mg dose of methylergonovine or a pharmaceutically acceptable sal...  
WO/2016/187558A3
A method of improving brain function in a hypothermic patient is provided. The method comprises administering to the patient an amount of a fibroblast growth factor 21 (FGF21) effective to increase RNA binding motif 3 (RBM3) production i...  
WO/2016/186772A2
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/185423A1
Disclosed are compounds having the formula: (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.  
WO/2016/183741A1
The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present i...  
WO/2016/184381A1
Provided is a use of dextrorotatory oxiracetam in the preparation of a drug for preventing or treating epilepsy. An experimental result shows that the dextrorotatory oxiracetam has an obvious effect in the treatment of generalized epilep...  
WO/2016/187228A1
Neonatal seizure is different from adult seizure, and many antiepileptic drugs that are effective in adults often fail to treat neonatal seizure. Gluconic acid, a natural organic acid enriched in fruits and honey, is shown herein to pote...  
WO/2016/184427A1
Disclosed are a mesenchymal stem cell hypoxically cultured and the use thereof, wherein the stem cell can relieve or treat inflammatory diseases, thereby producing an insulin-like growth factor-2 which plays a central role in the treatme...  
WO/2016/183578A1
A new class of quinoline compounds is useful for the detection and treatment of Alzheimer's disease and other neurodegenerative diseases such as amyloidoses and tauopathies. The compounds can be synthesized in radiolabeled form for use a...  
WO/2016/179645A1
The present disclosure relates to 4H-pyran compounds of formula (I) and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicam...  
WO/2016/182988A1
In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a CSF-IR inhibitor together with one or more additi...  
WO/2016/183252A1
The present disclosure provides for methods of treating a neurodegenerative condition, as well as methods for assessing the risk of developing a neurodegenerative condition, and assessing treatment efficacy in subjects who are carriers o...  
WO/2016/181894A1
The present invention provides a compound which has an excellent TLR4 signaling inhibitory effect and is useful as a prophylactic or therapeutic agent for diseases such as autoimmune diseases and/or inflammatory diseases, chemotherapy-in...  
WO/2016/182862A1
Formulations comprising recombinant human tripeptidyl peptidase- 1 (rhTPPl) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPPl in the prevention a...  
WO/2016/180751A1
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2016/183425A1
The invention relates to a micro-encapsulation system for immobilizing mesenchymal stem cells (MSCs), methods for delivery of encapsulated MSCs into the central nervous system, and use of the encapsulated cells as cellular transplantatio...  
WO/2016/181945A1
The purpose of the present invention is to provide a novel composition and solvent for facilitating the production of a brain-derived neurotrophic factor (BDNF) and a method for facilitating the production of BDNF. According to the prese...  
WO/2016/180870A1
The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.  
WO/2016/180981A1
The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl) carbonyl] indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof and its therapeutic uses in the treatment of neurodegenerative disorders, i...  
WO/2016/180472A1
A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune di...  
WO/2016/182036A1
The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemot...  
WO/2016/180247A1
The present invention relates to a bicyclic compound used as an Lp-PLA2 inhibitor, a preparation method and pharmaceutical use thereof, and a pharmaceutical composition containing the compound. The structure of the bicyclic compound is s...  
WO/2016/180879A1
The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS...  
WO/2016/183244A1
This disclosure is directed to a method of treating dependency on an opioid drug, including acute and post-acute withdrawal symptoms, comprising treating an opioid-dependent patient with noribogaine, noribogaine derivative, or pharmaceut...  
WO/2016/182840A1
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of th...  
WO/2016/179566A1
The present application relates to new uses of 5-HT6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-pip...  

Matches 251 - 300 out of 120,238